ARVN NASDAQ
Arvinas, Inc.
1W: -2.7%
1M: -0.8%
3M: -9.4%
YTD: -35.0%
1Y: -19.1%
3Y: -49.8%
5Y: -91.0%
$7.45
+0.14 (+1.92%)
Pre-Market: $7.52 (+0.07, +0.87%)
Weekly Expected Move ±7.7%
$6
$7
$7
$8
$8
Credit Risk of going bust: lower than 89% of companies Debt: 1.7% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Arvinas, Inc. would be worth roughly what it owes.
Total debt $8.2M against a stock market value of $480.7M.
Distance to default 12.91 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $350K (short-term plus half of long-term), stock volatility 55.2%; Altman Z'' 3.51. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), Arvinas, Inc. would be worth roughly what it owes.
Total debt $8.2M against a stock market value of $480.7M.
Distance to default 12.91 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $350K (short-term plus half of long-term), stock volatility 55.2%; Altman Z'' 3.51. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
10 relationships10
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2021-07-22
Earliest Filing
2025-01-22
Latest Filing
partner: 9
investor: 1
Counterparties (Filed by ARVN)
10 relationshipsCompanies named in ARVN's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Science Park Development Corporation | — | partner | Landlord in a lease termination agreement with Arvinas Operations, Inc. | 2025-01-22 | View |
| Science Park Development Corporation | — | partner | Landlord for the Eighth Building 5 Lease Amendment | 2025-01-06 | View |
| Science Park Development Corporation | — | partner | Landlord for lease amendments of Building 5 and Building 4 premises. | 2024-12-16 | View |
| Novartis Pharma AG | NVSEF | partner | Entered into a license and asset purchase agreement for PROTAC technology and AR-V7 rights. | 2024-04-11 | View |
| EcoR1 Capital, LLC | — | investor | Investor granted right to nominate a Class II director. | 2023-11-27 | View |
| Pfizer | PFE | partner | Collaboration partner mentioned in forward-looking statements. | 2023-11-27 | View |
| Foundation Medicine, Inc. | — | partner | Entered into a Master In Vitro Diagnostics Agreement for the development and commercialization of companion diagnostic a | 2022-06-09 | View |
| Piper Sandler & Co. | PIPR | partner | Sales agent for equity distribution agreement | 2021-08-06 | View |
| Cantor Fitzgerald & Co. | — | partner | Sales agent for equity distribution agreement | 2021-08-06 | View |
| Pfizer Inc. | PFE | partner | Entered into a collaboration agreement for co-exclusive rights to develop and commercialize ARV-471, plus a stock purcha | 2021-07-22 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-04 | Earnings Release; Exhibits | View | |
| 2026-06-25 | Shareholder Vote | View | |
| 2026-06-22 | Officer/Director Change | View | |
| 2026-06-16 | Other Events | View | |
| 2026-06-02 | Regulation FD; Other Events; Exhibits | View | |
| 2026-05-12 | Earnings Release; Exhibits | View | |
| 2026-05-12 | Material Agreement; Regulation FD; Exhibits | Agreement | View |
| 2026-05-01 | Regulation FD; Other Events; Exhibits | View | |
| 2026-03-18 | Regulation FD; Other Events; Exhibits | View | |
| 2026-02-24 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-02-12 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-12-08 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-24 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-10-20 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-10-06 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-09-17 | Costs Associated with Exit or Disposal Activities; Regulation FD Disclosure; Other Events; Financial | View | |
| 2025-08-08 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-08-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-09 | Departure/Election of Directors; Appointment of Officers | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR